Trial Profile
Pilot Study of Affinity-enhanced Anti-NY-ESO-1 TCR Engineered Autologous T Cells in NSCLC Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 16 Jan 2019 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
- 16 Jan 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2019.
- 07 Feb 2017 New trial record